Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for hematologic malignancies and is predicted to experience widespread use in the near future. However, not all risks associated with this novel approach are well defined. There are few data in the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ping, Zhou, Lili, Ye, Shiguang, Zhang, Wenjun, Wang, Junbang, Tang, Xiaochen, Liu, Jie, Xu, Yangyang, Qian, Wenbin, Liang, Aibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320511/
https://www.ncbi.nlm.nih.gov/pubmed/34335561
http://dx.doi.org/10.3389/fimmu.2021.638678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320511/
https://www.ncbi.nlm.nih.gov/pubmed/34335561
http://dx.doi.org/10.3389/fimmu.2021.638678

Ejemplares similares